$JAZZ
Jazz Pharmaceuticals PLC

2022 Q1 Form 10-Q Financial Statement

#000123252422000022 Filed on May 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $813.7M $607.6M
YoY Change 33.93% 13.62%
Cost Of Revenue $115.3M $40.20M
YoY Change 186.78% 40.07%
Gross Profit $698.4M $567.4M
YoY Change 23.09% 13.13%
Gross Profit Margin 85.83% 93.39%
Selling, General & Admin $308.8M $260.5M
YoY Change 18.54% 25.0%
% of Gross Profit 44.21% 45.91%
Research & Development $130.0M $76.57M
YoY Change 69.75% -11.07%
% of Gross Profit 18.61% 13.5%
Depreciation & Amortization $7.617M $4.779M
YoY Change 59.38% 5.57%
% of Gross Profit 1.09% 0.84%
Operating Expenses $438.8M $337.1M
YoY Change 30.17% 14.46%
Operating Profit $87.55M $162.1M
YoY Change -46.0% -185.47%
Interest Expense -$70.68M -$27.38M
YoY Change 158.2% 48.01%
% of Operating Profit -80.74% -16.89%
Other Income/Expense, Net
YoY Change
Pretax Income $6.325M $135.7M
YoY Change -95.34% -164.83%
Income Tax $500.0K $18.00M
% Of Pretax Income 7.91% 13.27%
Net Earnings $1.647M $121.8M
YoY Change -98.65% -177.19%
Net Earnings / Revenue 0.2% 20.05%
Basic Earnings Per Share $0.03 $2.16
Diluted Earnings Per Share $0.03 $2.09
COMMON SHARES
Basic Shares Outstanding 61.87M shares 56.47M shares
Diluted Shares Outstanding 62.91M shares 58.39M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $490.8M $2.433B
YoY Change -79.82% 147.81%
Cash & Equivalents $490.8M $2.098B
Short-Term Investments $80.71M $1.581B
Other Short-Term Assets $243.9M $147.7M
YoY Change 65.09% 56.66%
Inventory $985.5M $115.5M
Prepaid Expenses $117.4M $57.19M
Receivables $572.4M $414.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.501B $3.167B
YoY Change -21.03% 108.67%
LONG-TERM ASSETS
Property, Plant & Equipment $341.0M $123.9M
YoY Change 175.34% -4.4%
Goodwill $1.782B $938.4M
YoY Change 89.95% 3.21%
Intangibles $6.783B $2.108B
YoY Change 221.77% -5.83%
Long-Term Investments
YoY Change
Other Assets $35.51M $30.35M
YoY Change 16.99% -35.57%
Total Long-Term Assets $9.268B $3.590B
YoY Change 158.19% -2.92%
TOTAL ASSETS
Total Short-Term Assets $2.501B $3.167B
Total Long-Term Assets $9.268B $3.590B
Total Assets $11.77B $6.756B
YoY Change 74.19% 29.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $73.34M $77.74M
YoY Change -5.66% 17.24%
Accrued Expenses $604.7M $374.0M
YoY Change 61.67% 43.29%
Deferred Revenue $1.686M $2.373M
YoY Change -28.95% -43.18%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $31.00M $248.6M
YoY Change -87.53% 644.64%
Total Short-Term Liabilities $737.4M $752.1M
YoY Change -1.95% 89.86%
LONG-TERM LIABILITIES
Long-Term Debt $5.993B $1.853B
YoY Change 223.41% 17.5%
Other Long-Term Liabilities $124.6M $105.9M
YoY Change 17.74% -9.71%
Total Long-Term Liabilities $6.118B $1.959B
YoY Change 212.29% 15.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $737.4M $752.1M
Total Long-Term Liabilities $6.118B $1.959B
Total Liabilities $6.855B $2.711B
YoY Change 152.86% 29.69%
SHAREHOLDERS EQUITY
Retained Earnings $959.3M $1.282B
YoY Change -25.15% 66.26%
Common Stock $3.239B $2.695B
YoY Change 20.2% 17.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.608B $3.798B
YoY Change
Total Liabilities & Shareholders Equity $11.77B $6.756B
YoY Change 74.19% 29.55%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $1.647M $121.8M
YoY Change -98.65% -177.19%
Depreciation, Depletion And Amortization $7.617M $4.779M
YoY Change 59.38% 5.57%
Cash From Operating Activities $209.0M $285.0M
YoY Change -26.67% 4.41%
INVESTING ACTIVITIES
Capital Expenditures $12.29M $2.168M
YoY Change 466.97% -55.11%
Acquisitions
YoY Change
Other Investing Activities $0.00 $739.3M
YoY Change -100.0% 362.06%
Cash From Investing Activities -$37.29M $737.1M
YoY Change -105.06% -1326.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$270.8M $18.28M
YoY Change -1581.78% -112.38%
NET CHANGE
Cash From Operating Activities $209.0M $285.0M
Cash From Investing Activities -$37.29M $737.1M
Cash From Financing Activities -$270.8M $18.28M
Net Change In Cash -$100.6M $1.040B
YoY Change -109.68% 1518.11%
FREE CASH FLOW
Cash From Operating Activities $209.0M $285.0M
Capital Expenditures $12.29M $2.168M
Free Cash Flow $196.7M $282.8M
YoY Change -30.46% 5.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001232524
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Jazz Pharmaceuticals plc
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-33500
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 4
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62318745 shares
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1032470
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Fifth Floor, Waterloo Exchange,
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Waterloo Road
CY2022Q1 dei Entity Address Country
EntityAddressCountry
IE
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D04 E5W7
CY2022Q1 dei Country Region
CountryRegion
353
CY2022Q1 dei City Area Code
CityAreaCode
1
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
634-7800
CY2022Q1 dei Security12b Title
Security12bTitle
Ordinary shares, nominal value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
JAZZ
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
490835000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
591448000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
572392000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
563360000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
985454000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
1072721000 USD
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
117399000 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
131413000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
243888000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
252392000 USD
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
90888000 USD
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
0 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
2500856000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2611334000 USD
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
257632000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
256837000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
83412000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86586000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6783057000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7152328000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
1782444000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
1827609000 USD
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
314672000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
311103000 USD
CY2022Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
11336000 USD
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
12029000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
35508000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40813000 USD
CY2022Q1 us-gaap Assets
Assets
11768917000 USD
CY2021Q4 us-gaap Assets
Assets
12298639000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
73336000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100298000 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
726172000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
445462000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
87549000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
162119000 USD
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1222084000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1300541000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
124644000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
116998000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2022Q1 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 USD
CY2021Q4 jazz Nonvoting Euro Deferred Shares
NonvotingEuroDeferredShares
55000 USD
CY2022Q1 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 USD
CY2021Q4 jazz Capital Redemption Reserve
CapitalRedemptionReserve
472000 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3239327000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3534792000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-590720000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-400360000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
959347000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
830226000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3608487000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3965191000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11768917000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12298639000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
813721000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
607581000 USD
CY2022Q1 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
115284000 USD
CY2021Q1 jazz Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment
CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment
40189000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
308813000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
260508000 USD
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
129981000 USD
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
76573000 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
172094000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68192000 USD
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-70684000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-27376000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10540000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
943000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6325000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
604710000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
666304000 USD
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
31000000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
31000000 USD
CY2022Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
26677000 USD
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
9608000 USD
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1686000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2093000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
737409000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
809303000 USD
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
347000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
463000 USD
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5992868000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6018943000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83078000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87200000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
135686000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
536000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18019000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4142000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4165000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1647000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.16
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61865000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56468000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62907000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58393000 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1647000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-190488000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-46220000 USD
CY2022Q1 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax
-43000 USD
CY2021Q1 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax
0 USD
CY2022Q1 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax
128000 USD
CY2021Q1 jazz Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax
0 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
-166000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
1160000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Reclassification Adjustment Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterReclassificationAdjustmentTax
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Reclassification Adjustment Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterReclassificationAdjustmentTax
3000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
16000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190360000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45076000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-188713000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
76756000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3965191000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21729000 USD
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
33776000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50106000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190360000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1647000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3608487000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3659745000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50407000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
23784000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34565000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45076000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3797689000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1647000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
172094000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68192000 USD
CY2022Q1 jazz Inventory Step Up Value Adjustment
InventoryStepUpValueAdjustment
63943000 USD
CY2021Q1 jazz Inventory Step Up Value Adjustment
InventoryStepUpValueAdjustment
0 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
50070000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34485000 USD
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-45339000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-19110000 USD
CY2022Q1 jazz Noncash Interest Expense
NoncashInterestExpense
12168000 USD
CY2021Q1 jazz Noncash Interest Expense
NoncashInterestExpense
15688000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
7617000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
4779000 USD
CY2022Q1 jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
2170000 USD
CY2021Q1 jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
1083000 USD
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
14701000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7766000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9723000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18245000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
24812000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
22014000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23170000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2897000 USD
CY2022Q1 jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-3095000 USD
CY2021Q1 jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-3690000 USD
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-979000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-157000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-27617000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
51292000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-23241000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13719000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
16767000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
24625000 USD
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-523000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-637000 USD
CY2022Q1 jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-3915000 USD
CY2021Q1 jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-4182000 USD
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5130000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
4774000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
208979000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
284997000 USD
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 USD
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
760000000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12292000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2168000 USD
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
20700000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37292000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
737132000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21729000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
50407000 USD
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
33776000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
23784000 USD
CY2022Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
258764000 USD
CY2021Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
8347000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-270811000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18276000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1489000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-641000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-100613000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1039764000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
591448000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1057769000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
490835000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2097533000 USD
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
311103000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6018943000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
830226000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3534792000 USD
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div>We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
490835000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
490835000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
490835000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
591448000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
591448000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
591448000 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
200000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1200000 USD
CY2022Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
5000000 USD
CY2022Q1 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
8418000 USD
CY2021Q4 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
18419000 USD
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
26335000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
21550000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
775804000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
886849000 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
183315000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
164322000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
985454000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
1072721000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
1827609000 USD
CY2022Q1 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
12927000 USD
CY2022Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-32238000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
1782444000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7963673000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1331504000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6632169000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8210692000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1213350000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6997342000 USD
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8114561000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1331504000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6783057000 USD
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8365678000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1213350000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7152328000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
455447000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
607262000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
607262000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
607262000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
607262000 USD
CY2022Q1 jazz Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
3747674000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6632169000 USD
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
350328000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
342208000 USD
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
92696000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
85371000 USD
CY2022Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
257632000 USD
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
256837000 USD
CY2022Q1 jazz Deferred Tax Intercompany Profit Current
DeferredTaxIntercompanyProfitCurrent
205233000 USD
CY2021Q4 jazz Deferred Tax Intercompany Profit Current
DeferredTaxIntercompanyProfitCurrent
203480000 USD
CY2022Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
38655000 USD
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
48912000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
243888000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
252392000 USD
CY2022Q1 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
258649000 USD
CY2021Q4 jazz Accrued Rebates And Other Sales Deductions
AccruedRebatesAndOtherSalesDeductions
215397000 USD
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
126479000 USD
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
158870000 USD
CY2022Q1 jazz Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
27741000 USD
CY2021Q4 jazz Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
25612000 USD
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
21228000 USD
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
48640000 USD
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
19441000 USD
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
20345000 USD
CY2022Q1 jazz Sales Return Reserve
SalesReturnReserve
18749000 USD
CY2021Q4 jazz Sales Return Reserve
SalesReturnReserve
15814000 USD
CY2022Q1 jazz Accrued Inventory Related Liabilities
AccruedInventoryRelatedLiabilities
18708000 USD
CY2021Q4 jazz Accrued Inventory Related Liabilities
AccruedInventoryRelatedLiabilities
16166000 USD
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
17527000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
22507000 USD
CY2022Q1 jazz Lease Liability Current
LeaseLiabilityCurrent
16155000 USD
CY2021Q4 jazz Lease Liability Current
LeaseLiabilityCurrent
15763000 USD
CY2022Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
14666000 USD
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
21566000 USD
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8418000 USD
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
18419000 USD
CY2022Q1 jazz Accrued Construction In Progress
AccruedConstructionInProgress
3978000 USD
CY2021Q4 jazz Accrued Construction In Progress
AccruedConstructionInProgress
2894000 USD
CY2022Q1 jazz Accrued Milestones
AccruedMilestones
0 USD
CY2021Q4 jazz Accrued Milestones
AccruedMilestones
25000000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52971000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59311000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
604710000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
666304000 USD
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
6023868000 USD
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
6049943000 USD
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
31000000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
31000000 USD
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5992868000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6018943000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
23250000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
31000000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
606000000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
31000000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1031000000 USD
CY2022Q1 jazz Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
4429500000 USD
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6151750000 USD
CY2022Q1 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
74400000 USD
CY2022Q1 us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
-190488000 USD
CY2022Q1 us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
-128000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190360000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1647000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
121832000 USD
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61865000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56468000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1042000 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1584000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
341000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62907000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58393000 shares
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.16
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.09
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
813721000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
607581000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
813721000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
607581000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2556000 USD
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
523000 USD
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2033000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50070000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34485000 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
8823000 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
6753000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
41247000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
27732000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.008
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000000 USD
CY2022Q1 jazz Disposal Group Including Discontinued Operation Upfront Payment To Be Received
DisposalGroupIncludingDiscontinuedOperationUpfrontPaymentToBeReceived
53000000 USD
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Intangible Assets
DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
56680000 USD
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Inventory1
DisposalGroupIncludingDiscontinuedOperationInventory1
21163000 USD
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Goodwill1
DisposalGroupIncludingDiscontinuedOperationGoodwill1
12927000 USD
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Other Assets
DisposalGroupIncludingDiscontinuedOperationOtherAssets
118000 USD
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
90888000 USD

Files In Submission

Name View Source Status
0001232524-22-000022-index-headers.html Edgar Link pending
0001232524-22-000022-index.html Edgar Link pending
0001232524-22-000022.txt Edgar Link pending
0001232524-22-000022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jazz-20220331.htm Edgar Link pending
jazz-20220331.xsd Edgar Link pending
jazz-20220331_cal.xml Edgar Link unprocessable
jazz-20220331_def.xml Edgar Link unprocessable
jazz-20220331_htm.xml Edgar Link completed
jazz-20220331_lab.xml Edgar Link unprocessable
jazz-20220331_pre.xml Edgar Link unprocessable
jazzq12022ex101.htm Edgar Link pending
jazzq12022ex311.htm Edgar Link pending
jazzq12022ex312.htm Edgar Link pending
jazzq12022ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending